

bio forum

Central European



#CEBioForum2025

02-03 april '25

— Warsaw, Poland



Share your thoughts and impressions with tag

#CEBioForum2025

& join the discussion.



#CEBioForum2025

Magdalena Kulczycka, PhD
President of BioForum



Ladies and Gentlemen,

It is with great pleasure that I welcome you to CEBioForum 2025 - international meeting of biotech changemakers held since 25 years.

Global geopolitical shifts bring both challenges and opportunities - from market fluctuations to instability in the U.S., the world's largest biotech hub. Europe's biotech sector must act now. This year's conference goes beyond trends - it's about strategy and action. With changes in EU regulations, industry strategies, and startup adaptation, CEBioForum 2025 is a platform for navigating transformation.

Key discussions will focus on:

- Strengthening Europe's biotech position through funding, regulation, and partnerships
- AI and data-driven breakthroughs in drug discovery, precision medicine, and longevity
- Biotechnology's role in sustainability and circular economy
- Collaboration across the biotech ecosystem—startups, SMEs, CDMOs, and big pharma
- Securing biotech financing, investment trends, and risk assessment

We hope you leave CEBioForum 2025 not just inspired, but with a clear vision and concrete steps to advance your biotech projects, driving innovation, health, and industry growth.

Enjoy CEBioForum 2025 and I look forward to see you at next year edition!

*Magdalena
Kulczycka*



agenda

02 apr 2025

day 1

8:00-9:00	REGISTRATION
9:00-09:30	OPENING
	KEY NOTE 1 Salim Essakali
	COFFEE BREAK
10:45-11:45	PANEL #1 Interstellar - Europe's biotech presence on the global stage
11:45-12:25	BIOTECH PRESENTATIONS
12:30-13:00	BIOTECH TALK #1 Cracking the code - founders mindset
	LUNCH BREAK
14:00-14:30	BIOTECH PRESENTATIONS
14:30-15:15	PANEL #2 Blade Runner - Biotech Revolution and the Future of Longevity
	COFFEE BREAK
15:30-16:15	BIOTECH TALK #2 Lost in Translation - Bridging the gap between Biotech innovators and Investors
18:30-23:00	CEBIOFORUM AWARDS 2025 BANQUET

03 apr 2025


day 2

9:00-9:30	MORNING COFFEE
09:30-10:15	KEY NOTE 2 Torben V. Borchert, PhD
	COFFEE BREAK
10:30-11:15	PANEL #3 Mad Max world or Green Utopia - is biotech a solution?
11:15-11:45	BIOTECH PRESENTATIONS
11:45-12:15	BIOTECH TALK #3 Ocean's 25 - meet my partner in ...
	COFFEE BREAK
12:30-13:30	PANEL #4 The biotech Matrix - startups, SMEs, big pharma and ...?
13:30-14:00	PANEL #5 "From zero to pharma hero" - fundraising for biotech companies
	LUNCH & CLOSING



#CEBioForum2025

map



partnering app

discover the partnering app
dedicated to CEBioForum 2025
it includes:


- + agenda
- + floor plan
- + list of speakers
- + full list of attendees

Reach out to people you are looking
for & set up a B2B meeting during
#CEBioForum2025

scan for website



Check your email to find
your account password






#CEBioForum2025

partners & sponsors

+ honorary patronage



Honorary patronage
of the Mayor of Warsaw



UNIVERSITY
OF WARSAW



National Centre for Research
and Development



PAIH
PFR Group



Polish Investment
& Trade Agency
PFR Group

+ platinum partner



Life Science Executive Search



fields of competence



The European Association for Bioindustries

► PACTT

PRAGUE BIO



AGENOX

+ gold partner



+ silver partners



polpharma
biologics




#CEBioForum2025

attending companies



SGS

ALIGO
VENTURE CAPITAL

Bioceltix



boult




DENTONS

i&i
PragueDISCOVER
INTERNATIONAL

HAMILTON



IDEXX

INVEST
REGION LEIPZIG
GERMANYPERSONATHER
PERSONALIZED THERAPYCaptor
Therapeutics®

molecule

eConsulting



novo nordisk fonden

EVERSANA



ExcellGene

pratia
your platform for innovative medicine

Scope Fluidics



W2B lawyers

intertek
Total Quality. Assured.

Medical Inventi

Drinks of Life
MORE THAN DRINKS



opening session



Związek Firm Biotechnologicznych

Association of Biotechnology Companies BioForum

BioForum facilitates the sharing of information, research findings, and best practices among member companies. Moreover, BioForum represents the collective voice of its 40+ members when interacting with regulatory bodies, government agencies, and policymakers either at National level or European (as BioForum is member of EuropaBio – the European Association for Bioindustries). We advocate for policies that support the growth of the biotechnology sector, address industry challenges, and promote innovation. In order to do that, BioForum organizes a networking and collaboration conference – CEBioForum – for professionals in the field to connect, share ideas, and form partnerships.



Magdalena Kulczycka, PhD
President of BioForum



The European Association for Bioindustries

EUROPABIO – The European Association for Bioindustries

EuropaBio is the largest biotechnology industry association in Europe, representing the entire biotech ecosystem – from innovative startups to global leaders, along with national biotech associations. Since 1996, EuropaBio has worked to shape legislative, regulatory, and economic frameworks that support biotechnology as a driver of Europe's health, sustainability, and competitiveness. Acting as a key opinion leader, EuropaBio promotes the visibility of biotechnology and biomanufacturing, ensuring they are recognized as essential contributors to Europe's environmental, societal, and economic goals. Through its work, EuropaBio helps transform Europe's innovation potential into global leadership in biotechnology.



Claire Skentelberry
General Director of EuropaBio



keynote speakers

**Salim Essakali**

Vice President, Head of OEM Business
QIAGEN

Salim Essakali is an experienced leader in the life sciences and healthcare industries, currently serving as the Vice President and Head of OEM & Enzyme Business at QIAGEN, where he leverages over 20 years of expertise in business planning and executive strategy. His career spans various roles, including Head of Global Sales & Marketing at Solis BioDyne and Franchise Lead at Boston Scientific, where he contributed to pioneering medical technologies. Salim holds a Master's in Molecular Pathology and an MBA focused on Mergers & Acquisitions, bringing a unique blend of scientific and business acumen to drive innovation in medical devices, bioinformatics, and diagnostic solutions.

2 apr 2025 09:30-10:30

**Torben V. Borchert, PhD**

Scientific Director, Biotech
Novo Nordisk Foundation

The vision of the Novo Nordisk Foundation (NNF) is to improve people's health and the sustainability of society and the planet. To help society in the transition towards a circular bioeconomy, the Foundation supports predominantly research projects within biosolutions/biomanufacturing, agriculture and food science.

Torben V. Borchert is Scientific Director and responsible for the Biomanufacturing area in NNF. He holds a Ph.D. in chemical engineering from the Technical University of Denmark. Before joining NNF in 2021, **Torben** had various leadership roles within R&D and worked in biotech companies Novozymes (now Novonesis), Novo Nordisk and Dupont. Besides the leadership for Novozymes Discovery organization, he had responsibility for international research organizations in Denmark, India, China, and USA. He also serves as Adjunct Professor at DTU.

3 apr 2025 09:30-10:15



panel session

day 1

PANEL TITLE: **Interstellar – Europe's biotech presence on the global stage**

TIME: 10:45-11:45 | april 02 2025

TOPIC COVERED: Europe's scientific excellence holds immense potential, but to compete globally, the region must expand funding access, strengthen CDMO capabilities, and streamline collaboration across sectors. This panel will map out key strategies for boosting Europe's biotech competitiveness, focusing on investment priorities, regulatory improvements, and public-private partnerships to drive innovation, manufacturing capacity, and Europe's leadership in global biotech.

speakers at the panel session

**Łukasz Cioch**

Creative Director / LCMedia.pl

**Claire Skentelberry**

Director General / EuropaBio

**Łukasz Kościążuk**

Partner / CRIDO

**Salim Essakali**

Vice President and Head of OEM Business / QIAGEN

**Ireneusz Staroń**

Deputy President for Research Funding / Medical Research Agency

**Felix Faupel**

Chief Business Officer / Polpharma Biologics CDMO

**Kamil Garbera, PhD**

Research and Development, Business Development and Quality Director / TZF Polfa S.A



#CEBioForum2025

panel session

day 1

TALK TITLE: Cracking the code – founders mindset

TIME: 12:30-13:00 | april 02 2025

TOPIC COVERED: What does it take to lead in biotech? This panel explores the founder's mindset, balancing innovation, vision, and strategy in a competitive industry. Experts will discuss decision-making for all stakeholders, ensuring patient needs, investor expectations, and scientific progress align for maximum impact. Discover the wisdom behind creating value, sustaining innovation, and driving real change in biotech.

speakers at the panel session



Monika Kozdroń-Sikorska

Managing Partner / ExecMind



Louis Boon, PhD

CSO and Board Member / JJP Biologics

save the date

#CEBioForum2026

22-23 april '26

mark your calendars

bio
forum
Central European



panel session

day 1

PANEL TITLE: **Blade Runner - Biotech Revolution and the Future of Longevity**

TIME: 14:30-15:15, april 02 2025

TOPIC COVERED: From AI-powered drug discovery to microbiome-based therapies, the biotech revolution is redefining how we approach longevity and healthy aging. This panel explores how integrating genomic, microbiome, and real-world health data enables precision treatments, while experts discuss data challenges, personalized delivery methods, and how AI and biotech innovation will shape the future of longer, healthier lives.

speakers at the panel session



Prof. Marek Postuła
Co-Founder / Agenox



Mariusz Olejniczak
CEO / WPD Pharmaceuticals



Emil Syundyukov
CEO / Longenesis



Jarosław Biliński, MD, PhD
CEO / Human Biome Institute



Ricardo Gaminha Pacheco, MD, MBA
Strategic Partnering, Business Development & Licensing Director /
Insilico Medicine



panel session

day 1

TALK TITLE: *Lost in Translation - Bridging the gap between Biotech innovators and Investors*

TIME: 15:30-16:15 | april 02 2025

TOPIC COVERED: Biotech founders dream big, investors focus on ROI—how do we align these worlds? This talk explores the disconnects between innovation and investment, from risk perception to mismatched timelines. Experts will tackle funding challenges, exit strategies, and what makes biotech investable. Can we truly bridge this gap, or is being “lost in translation” inevitable?

speakers at the panel session



Karolina Jarosińska

Managing Director / ExecMind



Maciej Wieloch, PhD

Managing Partner / iff.vc



Marcin Sadlej

Managing Partner, Head of Corporate Finance / cc group



Jakub Baran

CEO / FamiCord AG



Jeremy Launder

CEO / Bioton S.A.



#CEBioForum2025

join

Związek Firm Biotechnologicznych BioForum

Association of Biotechnological Companies
BioForum

bio *forum*

Związek Firm Biotechnologicznych

to make an impact on development of
#polishbiotech

bioforum.pl



GreenBio2025

GreenBio forum

#GREENBIO



mark your calendars

GreenBio Forum 2025

is the 2nd edition of a key conference bringing together experts, scientists, and industry leaders to explore biotechnology-driven solutions for sustainable development. This event offers a unique opportunity to discover the latest innovations in the bioeconomy, build strategic partnerships, and discuss the future of the polish sector in the face of global climate and economic challenges.

23/10/2025

CIC, Warsaw, Poland





CEE - UK

BUILDING BRIDGES PROGRAM 2025

A strategic program helping **CEE healthcare companies** expand into the UK market through direct access to key stakeholders, investors, and life sciences networks.

KEY BENEFITS

- Access market insights, NHS decision-makers, and UK regulations
- Build partnerships with investors, accelerators, and research hubs
- Learn how to set up and grow your business in the UK
- Explore funding, grants, and NHS procurement pathways

Check out the Study Visit plan!



**Register
today!**



bioforum
a k c e l e r a t o r

The first **accelerator program** in Poland designed for young **biotech startups**!

- support from **mentors** tailored to your needs
- presentations and networking with **VC funds**
- a study visit to **Belgium**, **workshops** and **bootcamps** online and in Warsaw
- a chance to win **access to a lab**!

APPLY TODAY and take advantage of the opportunity to join during the program!



Not sure if the BioForum Accelerator suits your needs?

Schedule a meeting with Mateusz Sagan, MBA during CEBioForum2025!
Or write to us at akcelerator@bioforum.pl

DETAILS AND

REGISTRATION





presentations



day 1 | 02 apr 2025

11:45 - 11:55 KAWASKA Sp. z o. o

11:55 - 12:05 Polbionica S.A.

12:05 - 12:15 Acellmed

12:15 - 12:25 Sartorius

* 14:00 - 14:10 Onconick

14:10 - 14:20 CustomBiotech from Roche

14:20 - 14:30 IDEXX BioAnalytics



KAWASKA

Jarosław Korczyński, PhD

Title:**Leica Cell DIVE: Unlocking the Secrets of Tissue Microenvironments****Abstract:**

In the era of precision medicine, understanding the complex architecture of tissue microenvironments is crucial.

Leica Cell DIVE is a cutting-edge multiplex imaging system that enables researchers to analyze dozens of biomarkers in a single tissue sample with high spatial resolution. By utilizing iterative staining and fluorophore removal, it provides an unprecedented level of detail in cellular analysis.

This presentation will explore the technology behind Leica Cell DIVE, its applications in biomedical research, and its potential to revolutionize fields like oncology.

**POLBIONICA S.A.**

prof. Michał Wszoła MD, PhD

Polbionica S.A., MediSpace sp. z o.o., Fundacja Badań i Rozwoju Nauki

Title:**3D Bioprinting of organoids and organs for drug discovery and transplantation - a real disruptive innovation by Polbionica****Abstract:**

Alternative techniques like organ-on-a-chip, bioprinting and AI are replacing animal testing in drug development. 3D bioprinting enables the creation of vascularized models (pancreas, liver or cancer organoids) for drug testing, improving cost-efficiency and predictability. This study presents a bioprinting ecosystem, supporting the shift from animal models toward more accurate human-relevant systems.

**ACELLMED**

prof. Aleksander F. Sikorski

Title:

The use of liposome-based drug carriers in novel therapeutic solutions – Acellmed experience

Abstract:

Acellmed is a Polish biotech start-up focused on developing innovative therapeutic solutions using liposomal carriers, stem cells, microRNA and 3D printing. With a strong emphasis on ophthalmology, we are devoted to designing personalized therapies for viral, bacterial, and rare eye diseases. Our mission is to introduce innovations that improve people's health and the quality of life.

SARTORIUS**SARTORIUS**

Szymon Hołubowicz

Commercial Development Manager ATS

Title:

Simplifying Progress in Life Sciences and Bioprocessing

Abstract:

Join Sartorius' presentation to explore strategic initiatives and technological advancements in biopharmaceuticals, cell and gene therapies, and lab products. Discover how Sartorius, a global leader in life sciences, empowers scientists to develop innovative therapies and affordable medicines. Key themes include biopharmaceuticals' role in disease treatment, bioprocessing innovations, cell and gene therapy challenges, and sustainability goals. Gain insights into Sartorius' integrated solutions and collaborations shaping the future of life sciences.

**ONCONICK**

Daniel Krowarsch, PhD

Title: Anti-FGFR1 antibody drug conjugate for cancer treatment**Abstract:**

We developed a novel antibody-drug conjugate (ADC) highly specific for fibroblast growth factor receptor 1 (FGFR1), an oncogene associated with several types of cancer. Our molecule is highly specific and induced high cytotoxicity in FGFR1-positive cancer cells. Using two mouse xenograft models of human lung cancer, we showed that it is highly effective in eliminating tumours *in vivo*.

**ROCHE**

Frank Sima

KAM CustomBiotech CEE & CIS

Title:

CustomBiotech from Roche – Your strategic partner at every step of biomanufacturing

Abstract:

Roche CustomBiotech provides reliable, tailor-made and high-quality raw materials, kits and technologies to biopharma and diagnostics companies. Our quality raw materials are exceptionally well-suited for innovative Biopharma companies working on therapeutic approaches like mRNA-, immuno- and cell therapies.



#CEBioForum2025

**IDEXX Bioanalytics**dr Abdelhak MANSOURI
Senior Account Manager**Title:**
Research Forward: Cutting-Edge Testing Solutions & Health Monitoring**Abstract:**

IDEXX BioAnalytics supports researchers (academia/industry) by providing:

- Laboratory animal health Monitoring programs to ensure research integrity and animal wellbeing.
- Biologics & Cell Health authenticated and testing for contamination.
- Preclinical Testing to support your research needs.
- Free of charge scientific support for all the above-mentioned services.

**PERFECT MOMENT TO INVEST****ŁÓDŹ** [wudzh]**THE FASTEST DEVELOPING CITY IN POLAND****LOCAL ECONOMY - KEY FACTS:**

- CEE best communicated city
- Close proximity of 2 international airports (Łódź Airport – 15 min from the city centre, Warsaw Chopin Airport – 60 min by car)
- Central location and first in Poland completed ring road facilitating connections in all directions as well as a developed urban and suburban public transport system (bus, tram, agglomeration railway), CPK Airport – Central Polish Communication Hub (Including cargo project planned)
- Gateway to Western Europe – the intersection of main East-West and North-South routes enables quick connection to Berlin (less than 4 h), Prague, Vienna
- Cost effectiveness and easy access to the capital labour market at the same time
- Availability of highly qualified employees
- 1.2 mln people in the agglomeration in the range of regional train network
- Łódź is an expats friendly city, and a popular destination for students, specialists and managers as well as for manual workers from abroad
- 72 000 students
- Growing number of international students – 6 880 from over 100 countries

THE LIFE SCIENCE SECTOR IS A CORNERSTONE OF INNOVATION, ENCOMPASSING BIOTECHNOLOGY, CHEMISTRY, HEALTHCARE, AND MORE. BELOW IS AN OVERVIEW OF THE KEY FIGURES AND SUPPORTING INDUSTRIES DRIVING ITS GROWTH

CORE OF THE LIFE SCIENCE SECTOR**212**

- BIO-TECH 170
- BIO-CHEM 42

TOTAL LIFE SCIENCE ENTITIES

- BEAUTY 104
- FOODTECH 69
- MEDTECH 495
- PHARMA-TECH 25

**INVEST IN ŁÓDŹ****Contact:**

- boi@uml.lodz.pl
- facebook.com/lodzpl
- www.invest.lodz.pl
- [Invest in Łódź \(Central Poland\)](#)



awards

partner

POLSERVICE
PATENT AND TRADEMARK
ATTORNEYS OFFICE

partner


BIOTON

R&D Collaboration Award Celebrating projects that bridge research and entrepreneurship within the life sciences, leading to mutual advancements and tangible societal benefits. This award honors the collaborative spirit that drives innovation and practical applications in the field.

Innovative Startup Award Highlighting young companies that pioneer commercial ventures in biotechnology, medical devices, or bioinformatics. This award recognizes startups poised for market impact through innovative solutions and groundbreaking products.

Most Influencing Person Award Acknowledging an individual whose contributions have significantly shaped the trajectory of biotechnology in Poland, driving innovation and setting new standards in the field. This award celebrates visionary leadership and enduring impact on biotechnological development.

Jury Award Selected by our expert jury, this award recognizes the most compelling project across all entries, based on exceptional scientific merit or business potential. It celebrates outstanding innovation and the pursuit of excellence in life sciences.



jury members



Amine Benmoussa
Karista



Marta Kawczyńska
POLSERVICE



Małgorzata Masierek, PhD
Bioton S.A



Marian Popinigis
BioResearch Pharma S.A.



Eliza Kruczkowska
Polish Development Fund



Mateusz Sagan, MBA
European Innovation Council



Adriana Kiedzierska-Mencfeld, PhD
Polpharma Biologics S.A.



Delivering reliability every step of the way

Enabling the Life Sciences
Anytime, Anywhere.

- Temperature-controlled solutions
- Worldwide coverage
- Pharma and Biopharma Experts

Want to know more about
how we can work together?
Contact us!

contact@cryopdp.com | cryopdp.com



SCAN TO CONTACT US


*Come visit
our booth
#10L*



ALAB bioscience is a laboratory within the ALAB group, offering a wide range of research services for the Life Science, biomedical, preclinical and clinical sectors.

Our laboratories specialize in scientific, diagnostic and regulatory studies in the field of laboratory diagnostics, genetics, omics methods, pathomorphology, toxicology, and pharmacology - encompassing **basic, preclinical and clinical** research.

- Histopathology and digital pathology
- Toxicological pathology in GLP
- Laboratory, molecular and pathomorphological testing in Clinical Trials
- Olink Technology - it enables protein analyses performed using antibody kits labeled with DNA sequences.
- Biomark HD Platform - is a high-throughput genomic and proteomic analysis technology based on integrated fluidic circuits (IFCs) solutions.
- Sequencing - we perform transcriptomic testing based on NGS technology targeting both individual clients and preclinical studies.



Visit our website

ALAB bioscience in cooperation with ALAB sp. z o. o. • St. Stepinska 22/30 • 00-739 • Warsaw



panel session

day 2

PANEL TITLE: **Mad Max world or Green Utopia – is biotech a solution?**

TIME: 10:30-11:15 | april 03 2025

TOPIC COVERED: Can biotechnology drive a sustainable future? This panel explores green biotech innovations like biofuels, bioplastics, and carbon capture, reducing environmental impact. Experts will discuss circular economy solutions, from bio-based materials to waste-to-value technologies, showcasing real-world applications in industry and healthcare. Join us to discover how biotech is shaping a greener, more sustainable world

speakers at the panel session



Prof. Małgorzata Runiewicz-Wardyn
Faculty of Economics, Transformation,
Integration and Globalisation
Economic Research Center / Kozminski
University



Prof. Katarzyna Chojnacka
Vice-Rector for External
Relations / Wrocław University
of Science and Technology



Kamila Hrecka-Procińska
Senior Sustainability Development
Manager / Polpharma Biologics



Prof. Łukasz Drewniak
Vice-Dean for Finance, Faculty of
Biology / University of Warsaw



Torben V. Borchert, PhD
Scientific Director, Biotech / Novo
Nordisk Foundation



#CEBioForum2025

panel session

day 2

TALK TITLE: Ocean's 25 – meet my partner in ...

TIME: 11:45-13:15 | april 03 2025

TOPIC COVERED: Life Science Breakthroughs: Partner Up, Power Up! Innovation in Life Science is hard. That's why it is better to do it with partners. Let's listen to the stories of two amazing companies redefining transplantology and paving the way for first in region FDA approved biosimilar drugs. Lets see how partnerships are used to build hardware and software solutions leveraging data and AI in biotech and medtech.

speakers at the panel session



Łukasz Paciorkowski
Chief Strategy Officer / A4BEE



Przemysław Mazurek
CEO / Nanogroup S.A.



Bartłomiej Piernicki
Director Business Technology /
Polpharma Biologics



Clinmark transforms clinical research with innovative solutions and services, ensuring quality and compliance at every stage. Embrace ICH GCP R3 with us for successful trial outcomes!

Training Courses: Master ICH GCP R3!

Elevate your team's expertise with Clinmark's comprehensive training programs. Learn to navigate the complexities of ICH GCP R3 and ensure regulatory compliance with confidence

Process & Documentation Tune-Up: Optimize Your Clinical Processes!
Ensure compliance and efficiency with Clinmark's expert reviews of your clinical processes and documentation. From CRF design to audit trail assessments



SMART GLOBAL



DILIGENT EXPERTS



FAST&FLEXIBLE

#WeKnowWhatWeDo



panel session

day 2

PANEL TITLE: **The biotech Matrix – startups, SMEs, big pharma and ...?**

TIME: 12:30-13:30 | april 03 2025

TOPIC COVERED: The biotech ecosystem thrives on collaboration between startups, SMEs, CDMOs, and big pharma, where each player shapes innovation, scale-up, and commercialization. This panel explores how partnerships, competition, and evolving roles within the value chain drive biotech growth in Europe. Experts will discuss bridging research and manufacturing, fostering synergies, and boosting Europe's global competitiveness through stronger, smarter collaboration.

speakers at the panel session



Mateusz Sagan, MBA
Ambassador / European Innovation
Council



Łukasz Zybaczyński
CEO / BioResearch Pharma SA.



Dominik Lipka PhD Eng.
CTO, Member of the Board / SyVento
BioTech



Dawid Ignatowicz, MBA
Head of CDMO, Europe / Polpharma
API



Michał Szymanik, PhD
Business-Science Collaboration
Manager / Adamed



Charles Jonscher
Senior Partner / Clairfield
International



panel session

day 2

PANEL TITLE: „From zero to pharma hero” – fundraising for biotech companies

TIME: 13:30-14:00 | april 03 2025

TOPIC COVERED: Securing funding is a key challenge for biotech startups. This panel explores early-stage investment, from business angels to venture capital, and what makes a project attractive to funders. Experts will discuss VC vs. public funding, Big Pharma's interest in biotech, and milestone-based contracts. Gain insights into investor expectations, risk assessment, and trends shaping biotech financing.

speakers at the panel session



Wojciech Iwaniuk
CEO / Innervalue



Salim Essakali
Vice President and Head of OEM Business / QIAGEN



Tomasz Piec
Managing Investment Partner / Black Forest SICAV-SIF



Andrzej Bieniek
Investment Director / Esaliens



Marek Skibiński
Angel investor



presentations

day 2 | 03 apr 2025

11:15 - 11:25	Personather
11:25 - 11:35	Hamilton
11:35 - 11:45	SyVento BioTech

Title:

Development of anticancer targeted therapy based on small molecules regulating mutated RAS protein G12V POIR.01.02.00-00- 0034/15 NCBR

Abstract:

Personather LTD designed the first molecules to restore the GTPase activity of the RASG12V oncogene. The RASG12V oncogene is detected in many cancers, including lung, pancreatic, and colorectal cancer. These molecules show therapeutic potential: inhibition of the RAS-AKT pathway and higher cytotoxicity against cancer cells with the RASG12V mutation compared to normal cells. The molecules are protected by a patent application.biomedical research, and its potential to revolutionize fields like oncology.

Title:

Smart PAT - Shifting Biopharmaceuticals Quality Control to the Shop-Floor

Abstract:

Quality controls in biopharma production have traditionally been conducted off-line in laboratories, which significantly hampers process productivity. To enhance efficiency, there's a pressing need to transition to smart in-line Process Analytical Technology (Smart PAT). This transition encompasses:

- The adoption of real-time measurement technologies that can gauge Critical Process Parameters and Key Performance Indicators during the production cycle. Notable examples of these parameters and indicators include Viable Cell Density, Total Cell Density, and Dissolved Carbon-Dioxide.
- An increased emphasis on digitalization to pave the way for innovative process analytics. This includes the development of soft sensors like Viable Cell Count, the implementation of advanced process controls such as digital twin simulations, as well as initiatives in preventative maintenance and asset management.



#CEBioForum2025



SYVENTO

BIO
TECH

Dominik Lipka, PhD Eng.

CTO, Member of the Board / SyVento BioTech

Title:

The SyVento BioTech Solution to Overcoming Complex Challenges in Delivery, Development and Manufacturing of RNA-drug products

Abstract:

SyVento BioTech is an innovative, Polish biotech CDMO offering end-to-end capabilities to develop, manufacture, and formulate next-generation mRNA-based products and innovative medicines. With a state-of-the-art facility located in the central Europe, the company specializes in liposomal and LNP technology, providing tailored solutions for the encapsulation and delivery of therapeutic molecules, including small molecules, RNA, DNA, and proteins.

Leveraging unique know-how and customer-centric flexibility, SyVento BioTech delivers comprehensive services, including preclinical/clinical drug development, RUO/GMP-grade API production (mRNA), the manufacturing of commercial and clinical batches, and sterile fill & finish—all under one roof.

SyVento Biotech has opened its new mRNA manufacturing facility, a FlexFactory, spanning over 7 000 m², including lab and production areas, offices, and shared spaces. This development represents a significant milestone for SyVento Biotech, enabling the CDMO to accelerate and enhance their service offerings to medicine manufacturers.

It also establishes SyVento Biotech as a pioneer in the Polish market as it is the first mRNA FlexFactory in the country and the first in Europe equipped with the Historian automation system.

SyVento Biotech Unique Selling Proposition

- Providing end-to-end solutions including preclinical/clinical drug development, LNP/ liposomal formulation development, manufacturing and aseptic fill & finish
- Broad range of additional services including analytical development, validation, regulatory support and project management
- Housing drug and formulation development, cGMP manufacturing and aseptic F&F in the same facility
- RUO/GMP-grade mRNA production on site with scale-up to commercial manufacturing
- Aseptic sterile liquid manufacturing for wide range of injectable drug products (vials, pre-filled syringes/PFS & cartridges)
- Clinical & commercial batches production from 1mL to 100L



Follow #CEBioForum2026 and **join us** next year

22 - 23 april '26

at Central European BioForum conference.



With appreciation
to our trusted **Media Partners** 



RynekZdrowia.pl



#CEBioForum2025



#CEBioForum2025



designed by: 8b.design / www.8b.design / hello@8b.design